婴儿KMT2A重排急性淋巴细胞白血病微小残留病检测的临床意义:Interfant-06方案分析
本研究在Interfant-06方案治疗的249例KMT2A重排婴儿ALL中,于诱导结束(EOI)和巩固结束(EOC)时用PCR检测微小残留病(MRD)。EOI和EOC MRD水平均能预测结局,且不同巩固方案(淋系 vs 髓系)对EOI MRD不同层次患者的疗效存在差异。
要点
- EOI和EOC MRD水平均可预测婴儿KMT2A重排ALL的6年DFS,水平越高预后越差。
- 高EOI MRD婴儿可能从AML样巩固获益(DFS 45.9% vs 23.2%)。
- 低EOI MRD婴儿可能从ALL样巩固获益(DFS 78.2% vs 45.0%)。
核心结论
- 诱导治疗可筛选适合后续治疗的患者:高EOI MRD者可能受益于AML样巩固,低EOI MRD者可能受益于ALL样巩固。
- EOC MRD阳性患者结局极差。
研究设计与样本
- 在Interfant-06方案治疗的249例婴儿中,采用基于DNA的PCR检测重排的KMT2A、免疫球蛋白和/或T细胞受体基因,于EOI和EOC时评估MRD。
- MRD结果分类为阴性、中水平(<5×10^-4)和高水平(≥5×10^-4)。
关键数值与推荐
- MRD阴性、中水平(<5×10^-4)和高水平(≥5×10^-4)的定义。
- 高EOI MRD患者髓系巩固与淋系巩固的6年DFS分别为45.9% vs 23.2%。
- 低EOI MRD患者淋系巩固与髓系巩固的6年DFS分别为78.2% vs 45.0%。
临床怎么用
- 根据EOI MRD水平选择巩固方案:高EOI MRD考虑AML样巩固,低EOI MRD考虑ALL样巩固。
- EOC MRD阳性提示预后极差,需考虑强化治疗或干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Infant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of KMT2A gene rearrangements and poor outcome. We evaluated the value of minimal residual disease (MRD) in infants with KMT2A-rearranged ALL treated within the Interfant-06 protocol, which compared lymphoid-style consolidation (protocol IB) versus myeloid-style consolidation (araC, daunorubicin, etoposide/mitoxantrone, araC, etoposide). MATERIALS AND METHODS: MRD was measured in 249 infants by DNA-based polymerase chain reaction of rearranged KMT2A, immunoglobulin, and/or T-cell receptor genes, at the end of induction (EOI) and end of consolidation (EOC). MRD results were classified as negative, intermediate (< 5 × 10-4), and high (≥ 5 × 10-4). RESULTS: EOI MRD levels predicted outcome with 6-year disease-free survival (DFS) of 60.2% (95% CI, 43.2 to 73.6), 45.0% (95% CI, 28.3 to 53.1), and 33.8% (95% CI, 23.8 to 44.1) for infants with negative, intermediate, and high EOI MRD levels, respectively (P = .0039). EOC MRD levels were also predictive of outcome, with 6-year DFS of 68.2% (95% CI, 55.2 to 78.1), 40.1% (95% CI, 28.1 to 51.9), and 11.9% (95% CI, 2.6 to 29.1) for infants with negative, intermediate, and high EOC MRD levels, respectively (P < .0001). Analysis of EOI MRD according to the type of consolidation treatment showed that infants treated with lymphoid-style consolidation had 6-year DFS of 78.2% (95% CI, 51.4 to 91.3), 47.2% (95% CI, 33.0 to 60.1), and 23.2% (95% CI, 12.1 to 36.4) for negative, intermediate, and high MRD levels, respectively (P < .0001), while for myeloid-style-treated patients the corresponding figures were 45.0% (95% CI, 23.9 to 64.1), 41.3% (95% CI, 23.2 to 58.5), and 45.9% (95% CI, 29.4 to 60.9). CONCLUSION: This study provides support for the idea that induction therapy selects patients for subsequent therapy; infants with high EOI MRD may benefit from AML-like consolidation (DFS 45.9% v 23.2%), whereas patients with low EOI MRD may benefit from ALL-like consolidation (DFS 78.2% v 45.0%). Patients with positive EOC MRD had dismal outcomes. These findings will be used for treatment interventions in the next Interfant protocol.
引用
- Stutterheim J, van der Sluis IM, de Lorenzo P, et al. Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. J Clin Oncol. 2021. PMID: 33405950. doi:10.1200/JCO.20.02333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。